Literature DB >> 7564036

[Significance of combined use of anticoagulants and antiplatelet agents in the early stage after prosthetic valve replacement].

H Toyohira1, K Nakamura, H Kariyazono, K Yamada, Y Moriyama, S Shimokawa, H Saigenji, A Taira.   

Abstract

Patients who had undergone prosthetic valve replacement were treated with warfarin (anticoagulant) alone or in combination of ticlopidine (200 mg/day) or aspirin (81 mg/day) (anti-platelet agents). The study of blood coagulation factors and platelet aggregation were carried out with these cases. 1) The patients (n = 24) receiving warfarin for 21 days after prosthetic valve replacement revealed marked increases in PIVKA-II and vitamin K1-epoxide. The protein C activity was significantly lower than that before the operation. High levels of more than 5 ng/ml of TAT were found before operation and after warfarin administration for 21 days. 2) Warfarin did not affect platelet aggregation, whereas ticlopidine inhibited ADP-induced platelet aggregation and aspirin inhibited both collagen-induced and arachidonic acid-induced aggregation. In conclusion, combined use of anticoagulants and antiplatelet agents after prosthetic valve replacement will suppress not only the blood coagulation but also the platelet aggregation systems.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7564036

Source DB:  PubMed          Journal:  Kyobu Geka        ISSN: 0021-5252


  1 in total

Review 1.  Antiplatelet and anticoagulation for patients with prosthetic heart valves.

Authors:  David R Massel; Stephen H Little
Journal:  Cochrane Database Syst Rev       Date:  2013-07-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.